Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease? - A [99mTc]-TRODAT-1 SPECT study

Movement Disorders

Volumn 22, Issue 6, 2007, Pages 863-866

  Ming, Chi Shih ^a,b   De Andrade, Luiz Augusto Franco ^b   Amaro Jr , Edson ^b   Felicio, Andre Carvalho ^a   Ferraz, Henrique Ballalai ^a   Wagner, Jairo ^b   Hoexter, Marcelo Queiroz ^a   Li, Fu Lin ^c   Ying, Kai Fu ^c   Mari, Jair Jesus ^a   Tufik, Sergio ^a   Bressan, Rodrigo Affonseca ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c Institute of Nuclear Energy Research (INER)   (Thailand)

Author keywords

Dopamine transporter; Early and late onset Parkinson's disease; SPECT; TRODAT

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE; DOPAMINE TRANSPORTER; TECHNETIUM 99M; TRACER;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; IMAGING; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL; NIGRONEOSTRIATAL SYSTEM; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SCANNING ELECTROCHEMICAL MICROSCOPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION;

ADULT; AGE OF ONSET; AGED; CORPUS STRIATUM; DEPRESSION; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 34249096090     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21315     Document Type: Article

References (15)

1. Schestatsky P, Zanatto VC, Margis R, et al. Quality of life in a Brazilian sample of patients with Parkinson's disease and their caregivers. Res Bras Psiquiatr 2006;28:209-211.
2. Butterfield PG, Valanis BG, Spencer PS, et al. Environmental antecedents of young-onset Parkinson's disease. Neurology 2006; 43:1150-1158.
3. Leenders KL. Neuroimaging methods applied in Parkinson's disease. J Neurol 2004;251(Suppl. 6):VI/7-VI/12.
4. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med 1995;36:1175-1181.
5. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 2006;5:355-363.
6. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988;38:1402-1406.
7. Nagasawa H, Tanji H, Itoyama Y, et al. Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography. J Neurol Sci 1996;144:70-76.
8. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002;125:2248-2256.
9. Antonini A, Moresco RM, Gobbo C, et al. Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). Neurol Sci 2002;23(Suppl. 2):S51-S52.
10. Shih MC, Amaro JrE, Ferraz HB, et al. Neuroimaging of the dopamine transporter in Parkinson's disease - first study using [99mTc]-TRODAT-1 and SPECT in Brazil. Arg Neuropsiquiatr 2006;64:628-634.
11. Choi SR, Kung MP, Plossl K, et al. An improved kit formulation of a dopamine transporter imaging agent: [Tc-99m]TRODAT-1. Nucl Med Biol 1999;26:461-466.
12. De La Fuente-Fernandez R, Lim AS, Sossi V, et al. Age and severity of nigrostriatal damage at onset of Parkinson's disease. Synapse 2003;47:152-158.
13. Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with [123]I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-1456.
14. Kondo T. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J Neurol 2002;249(Suppl. 2):II25-II29.
15. Gomez Arevalo G, Jorge R, Garcia S, et al. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Mov Disord 1997;12:277-284.